WO1998010088A1 - Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 - Google Patents
Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 Download PDFInfo
- Publication number
- WO1998010088A1 WO1998010088A1 PCT/US1997/015716 US9715716W WO9810088A1 WO 1998010088 A1 WO1998010088 A1 WO 1998010088A1 US 9715716 W US9715716 W US 9715716W WO 9810088 A1 WO9810088 A1 WO 9810088A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- host cell
- vector
- recombinant
- rep
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- Adeno-associated virus is a replication- deficient parvovirus, the genome of which is about 4.6 kb in length, including 145 nucleotide inverted terminal repeats (ITRs) .
- the single-stranded DNA genome of AAV contains genes responsible for replication (rep) and formation of virions (cap) .
- rep nucleotide inverted terminal repeats
- cap nucleotide inverted terminal repeats
- AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells.
- Various groups have studied the potential use of AAV in the treatment of disease states.
- T7 RNA polymerase is the product of T7 gene 1, which can recognize its responsive promoter sequence specifically and exhibit a high transcriptase activity [M. Chamberlin et al, Nature - ££8_:227-231 (1970); J. Dunn and F. Studier, J. Mol.
- the present invention provides an inducible method for efficient production of rAAV which makes use of T7 polymerase.
- T7 Pol is derived from lambda phage and its promoter is not active in mammalian cells.
- expression of rep/cap can be controlled by placing these genes under control of the T7 promoter and providing the T7 Pol in trans or under the control of an inducible promoter.
- This method avoids the toxic effects of rep which rendered prior art methods of producing rAAV inefficient.
- the method of the invention is particularly suitable for large scale production of rAAV, which is desired for rAAV vectors to be used in gene therapy.
- the invention provides a method of producing rAAV which utilizes three vectors.
- a first vector is capable of expressing T7 polymerase in the host cell following transfection or infection.
- a second vector comprises the AAV rep and cap genes under the control of T7 promoter sequences (T7/rep/cap) .
- the third vector comprises a cassette containing 5 • and 3 ' AAV inverted terminal repeats (ITRs) flanking a selected transgene.
- ITRs inverted terminal repeats
- the invention provides a method in which a host cell is stably transfected with one of the three components of the system used in the triple infection system. The remaining components are introduced into the host cell, as described above.
- the invention provides method in which a vector containing T7 /rep /cap and a vector containing a cassette comprising a selected minigene flanked by 5 1 and 3' AAV ITRs are introduced into a host cell expressing T7 polymerase. The host cell is then cultured under conditions which permit production of rAAV.
- this invention provides a method which utilizes a host cell stably transfected with a plasmid containing T7 /rep/cap.
- a vector containing T7 pol and a vector containing a cassette comprising 5' AAV inverse terminal repeat (ITR), a selected minigene, and 3' AAV ITR are introduced into the host cell.
- the host cell is cultured under conditions which permit production of rAAV.
- the invention provides a method which utilizes a host cell stably transfected with a rescuable rAAV cassette.
- a vector containing T7 pol and a vector containing T7 /rep/ cap are introduced into the host cell.
- the host cell is cultured under conditions which permit production of rAAV.
- the present invention provides a method which utilizes a host cell stably transfected with two of the three components of the system used in the triple infection system. The remaining component is then introduced into the host cell, as described above.
- the present invention provides a method which utilizes a host cell stably transfected with the three components of the system used in the triple infection system.
- the T7 Pol is controlled by an inducible promoter.
- the invention provides a rAAV produced according to the method of the invention.
- Fig. 1 provides a schematic illustration of the construction of a recombinant adenovirus containing the T7 polymerase gene.
- Fig. 2 provides a schematic illustration of the construction of a recombinant plasmid containing the AAV rep/cap genes under control of a T7 promoter.
- Fig. 3 provides a schematic illustration of the construction of a recombinant adenovirus containing the rep/cap genes under control of a T7 promoter.
- Fig. 4 provides a schematic illustration of the construction of a recombinant hybrid Ad/AAV virus.
- the invention provides an inducible method for efficient production of recombinant AAV vectors useful particularly for gene delivery and transfer. Specifically, the invention provides methods of AAV production in which expression of the toxic but necessary rep gene is controlled by the T7 promoter.
- the method of the invention for production of rAAV involves introducing into a host cell the AAV rep and cap genes under control of a T7 promoter, and a recombinant adeno-associated virus (rAAV) cassette containing a selected minigene flanked by AAV ITRs.
- rAAV adeno-associated virus
- Upon introduction of a gene encoding T7 pol high level expression of rep protein from the T7/rep/cap construct is induced and cells may be grown on a large scale.
- the cells are caused to express the T7 polymerase which acts on the T7 promoter. This facilitates the efficient replication and packaging of rAAV carrying a gene of interest.
- a host cell may be triple transfected (or infected) with vectors containing the above elements.
- a host cell which expresses one or more of the required elements and may be transfected/infected with the remaining elements is utilized.
- a host cell which stably expresses all three elements of the system, and the T7 pol is placed under the control of an inducible promoter, which permits rep/cap expression to be controlled and the avoidance of toxic effects to the cell.
- adenoviral constructs are currently preferred.
- a different viral (adenoviral or non-adenoviral) or a plasmid vector which is capable of driving expression of the desired genes in the host cell.
- vectors carrying the required elements of this system e.g., the T7 polymerase, may be readily constructed using retroviruses. Therefore, this invention is not limited by the virus or plasmid selected for purposes of introducing the T7 pol, T7/rep/cap, or AAV cassette into the host cell.
- At least one of the vectors is a virus which provides the necessary helper functions to enable packaging.
- the helper functions may be provided by a co-transfected adenovirus or herpesvirus. Suitable techniques for introducing these vectors into the host cell are discussed below and are known to those of skill in the art.
- a "host cell” is any cell (cell line) , preferably mammalian, which permits expression of the T7 pol and T7/rep/cap and packaging of the rAAV containing the cassette, under the conditions described herein. Suitable packaging cells are known, and may be readily selected by the skilled artisan.
- a host cell used for assembly and packaging of recombinant AAV may be transfected with plasmid vectors or infected with viral vectors containing the required components of the system.
- a first vector contains the T7 Pol gene under the control of a suitable promoter.
- the nuclear localized T7 Pol gene is obtained from a publicly available plasmid [M. Strauss, Nucleic Acid Res.. 12:8485-8493 (1989)]. However, the gene may alternatively be obtained from other commercial and academic sources, including the American Type Culture Collection (pTF7-3, Accession No. 484944). See, also GenBank accession number M30308. Desirably, the T7 pol gene is linked to a nuclear localization signal, such as that described in Dunn, Gene. 6JJ:259-266 (1988), using conventional techniques.
- T7 Pol is under the control of a cytomegalovirus (CMV) immediate early promoter/enhancer [see, e.g., Boshart et al, Cell. 41:521-530 (1985)].
- CMV cytomegalovirus
- suitable promoters may be readily selected by one of skill in the art.
- Useful promoters may be constitutive promoters or regulated (inducible) promoters, which will enable control of the amount of the transgene to be expressed.
- another suitable promoter includes, without limitation, the Rous sarcoma virus LTR promoter/enhancer.
- Still other promoter/enhancer sequences may be selected by one of skill in the art.
- the vector also includes other conventional regulatory elements necessary to drive expression of T7 Pol in a cell transfected with the vector.
- regulatory elements are known to those of skill in the art.
- the second vector component of this system contains the rep and cap genes under control of a T7 promoter.
- the rep and cap genes can be obtained from a variety of known sources. See, e.g., T. Shenk, J. Virol.. 61:3096-3101 (1987), which provides the AAV2 genome within the plasmid psub20l; E. W. Lusby et al, J. Virol. , 4_l: 518-526 (1982) and J. Smuda and B.J. Carter, Virology. 1 :310-318 (1991).
- T7 promoter sequences can be obtained from a variety of known sources. See, e.g., T. Shenk, J. Virol.. 61:3096-3101 (1987), which provides the AAV2 genome within the plasmid psub20l; E. W. Lusby et al, J. Virol. , 4_l: 518-526 (1982) and J. Smuda and B.J. Carter,
- the vector further contains the sequence of untranslated region (UTR) of encephalomyocarditis (EMCV) downstream of the T7 promoter.
- UTR untranslated region
- EMCV encephalomyocarditis
- the vector also includes conventional regulatory elements necessary to drive expression of the rep/cap in a cell transfected with the vector.
- regulatory elements are known to those of skill in the art.
- the third vector component contains a rAAV cassette containing a minigene flanked by AAV ITRs.
- a minigene contains a suitable transgene, a promoter, and other regulatory elements necessary for expression of the transgene.
- the AAV sequences employed are preferably limited to the cis-acting 5 ' and 3 ' inverted terminal repeat (ITR) sequences [See, e.g., B. J. Carter, in "Handbook of Parvoviruses" , ed. , P. Tijsser, CRC Press, pp.155-168 (1990)]. Desirably, substantially the entire 143 bp sequences encoding the ITRs are used in the vectors.
- AAV ITR sequences may be obtained from any known AAV, including presently identified human AAV types. Similarly, AAVs known to infect other animals may also be employed in the vector constructs of this invention. The selection of the AAV is not anticipated to limit the following invention.
- a variety of AAV strains, types 1-4, are available from the American Type Culture Collection or available by request from a variety of commercial and institutional sources. In the following exemplary embodiment an AAV-2 is used for convenience.
- the 5 • and 3 • AAV ITR sequences flank a minigene which is made up of a selected transgene sequence and associated regulatory elements.
- the transgene sequence of the vector is a nucleic acid sequence heterologous to the AAV sequence, which encodes a polypeptide or protein of interest.
- the transgene is operatively linked to regulatory components in a manner which permits transgene transcription.
- transgene sequence will depend upon the use to which the resulting vector will be put.
- one type of transgene sequence includes a reporter sequence, which upon expression produces a detectable signal.
- reporter sequences include without limitation an E. coli beta- galactosidase (LacZ) cDNA, an alkaline phosphatase gene and a green fluorescent protein gene. These sequences, when associated with regulatory elements which drive their expression, provide signals detectable by conventional means, e.g., ultraviolet wavelength absorbance, visible color change, etc.
- a more preferred transgene sequence includes a therapeutic gene which expresses a desired gene product in a host cell.
- These therapeutic nucleic acid sequences typically encode products which may be administered to a patient in vivo or ex vivo to replace or correct an inherited or non- inherited genetic defect or treat an epigenetic disorder or disease.
- the selection of the transgene sequence is not a limitation of this invention.
- the minigene also includes conventional regulatory elements necessary to drive expression of the transgene in a cell transfected with the vector carrying the AAV cassette.
- the minigene contains a selected promoter which is linked to the transgene and located within the minigene, between the AAV ITR sequences of the vector.
- promoter which mediates expression of the transgene is a routine matter and is not a limitation of the vector.
- Useful promoters include those which are discussed above in connection with the first vector component.
- the minigene will also desirably contain heterologous nucleic acid sequences including sequences providing signals required for efficient polyadenylation of the transcript and introns with functional splice donor and acceptor sites.
- a common poly-A sequence which is employed in the exemplary vectors of this invention is that derived from the papovavirus SV-40. The poly-A sequence generally is inserted following the transgene sequences and before the 3* AAV ITR sequence.
- a common intron sequence is also derived from SV-40, and is referred to as the SV-40 T intron sequence.
- a minigene of the present invention may also contain such an intron, desirably located between the promoter/enhancer sequence and the transgene. Selection of these and other common vector elements are conventional and many such sequences are available [see, e.g., Sambrook et al, and references cited therein].
- the rAAV vector containing the AAV ITRs flanking the minigene may be carried on a plasmid backbone and used to transfect a selected host cell or may be flanked by viral sequences (e.g., adenoviral sequences) which permit it to infect the selected host cell.
- viral sequences e.g., adenoviral sequences
- Suitable Ad/AAV recombinant viruses may be produced in accordance with known techniques. See, e.g., WO 96/13598, WO 95/23867, and WO 95/06743, which are incorporated by reference herein.
- a cell line stably transfected with T7 rep/cap may be double transfected (infected) with a vector carrying T7 pol and a vector carrying the rAAV cassette, as illustrated in the following table.
- a cell line which contains a rescuable rAAV cassette may be double transfected (infected) with a vector containing T7 Pol and a vector containing T7/rep/cap, as illustrated in the following table.
- a stable cell line of the invention can be produced by transfection of a desired cell, e.g., 293 cells or other packaging cell lines expressing required adenoviral genes, with a plasmid containing the desired gene, e.g., T7 Pol, using conventional techniques and selected via an accompanying resistant marker gene. Depending upon whether inducible or constitutive expression is desired, an appropriate promoter may be selected.
- the cell may be transfected with a plasmid containing T7 Pol under control of a metallothionein promoter.
- a host cell constitutively expressing T7 Pol it may be inserted under control of a RSV or CMV promoter. Similar techniques may be used for providing a host cell containing the T7/rep/cap and a host cell containing a rescuable rAAV. The examples below describe production of stable cell lines. However, one of skill in the art could readily produce such cell lines using other conventional techniques. See, generally, Ausubel et al, Current Protocols in Molecular Biology (Wiley Interscience 1987) .
- a cell line which stably expresses two of the components of this system may be constructed, and then transfected (or infected) with a vector containing the remaining component of the system, as described above.
- a cell line is utilized which is stably transfected with the T7/rep/cap and a rescuable rAAV.
- the cell line is then transfected or infected with a vector containing the T7 pol.
- the cell line is stably transfected with the T7 pol and a rescuable rAAV.
- the cell line is then transfected or infected with a vector containing the T7 rep/cap.
- a cell line which stably expresses all three of the components of this system may be constructed and utilized in the method of the invention.
- a suitable packaging cell line is constructed which contains the rAAV, the T7/rep/cap and the T7 pol.
- the T7 Pol is placed under the control of an inducible promoter. Suitable inducible promoters are known to those of skill in the art and are discussed herein.
- T7 Pol may be placed under control of a metallothionein promoter. In this manner, expression of the T7 Pol, and thus the rep/cap, which are under control of the T7 promoter can be regulated and toxic effects to the cell avoided.
- Assembly of the selected DNA sequences of the adenovirus, AAV and the reporter genes or therapeutic genes and other vector elements into the vectors described above utilize conventional techniques.
- Such techniques include cDNA cloning such as those described in texts [Sambrook et al, cited above], use of overlapping oligonucleotide sequences of the adenovirus or AAV genome, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence.
- HEK human embryonic kidney
- Other conventional methods employed in this invention include homologous recombination of the viral genomes, plaquing of viruses in agar overlay, methods of measuring signal generation, and the like.
- the host cell Following infection/transfection, the host cell is then cultured under standard conditions, to enable production of the rAAV. See, e.g., F. L. Graham and L. Prevec, Methods Mol. Biol.. 7:109-128 (1991). Desirably, once the rAAV is identified using conventional techniques, it may be isolated using standard techniques and purified.
- Figure 1 provides a schematic of the construction of the recombinant adenovirus carrying the T7 polymerase.
- pMTT7N The plasmid pMTT7N was obtained from Dr. Michael Strauss [A. Lieber et al, Nucl. Acids Res.. 12:8485-8493 (1989)].
- pMTT7N contains a N-terminal nuclear location signal of SV40 large T antigen fused to the T7 Pol gene (T7N Pol) which is linked to the polyadenylation sequence of SV40. Expression is driven by the inducible mouse metallothionein promoter.
- the pMTT7N plasmid DNA was digested with Bglll and PvuII restriction enzymes and the fragments separated on an agarose gel.
- pAd.CMV.link.l is a plasmid containing the adenoviral sequences 0 to 16 map units deleted of Ela and Elb into which a CMV promoter-polylinker cassette was cloned. This is described in X. Ye et al, J. Biol. Chem.. 271:3639-3646 (1996).
- the expression unit of T7 Pol is directed by the CMV promoter.
- the promoter for the T7 Pol gene is linked to a PolyA tail as a cassette within the sequence of adenovirus 0-1 map unit (mu) and 9-16 mu.
- the pAd.CMV.T7N is linearized by Nhe I digestion and co- transfected with Cla I linearized Addel327 backbone using Cellphate kit (Pharmacia) . Approximately 1 week post- transfection, the T7 Pol adenovirus can be isolated from the plaques for further purification.
- a cell line stably expressing T7 Pol is established by co-transfection of plasmids pMTT7N and pMTCB6+ (which provides a selective marker) [K. H. Choo et al, SNA, 5:529-538; Eur. J. Biochem.. 124:417-424] into 293 cell at a ratio of 10:1 using calcium phosphate precipitation [F. Graham and A. van der Eb, Virol.. 5_2:456-467 (1973)].
- Colony cloning is carried out by Geneticin selection at a concentration of 1 mg/ml. Each clone obtained is transfected with pT7 rep/cap plasmid [see. Example 3 below] and analyzed for its ability to induce the expression of Rep protein upon induction by supplementation with Zn ++ .
- the T7N Pol obtained by Bglll/PvuII digestion of pMTT7N, as described above was subcloned downstream of RSV promoter at the cloning sites of BamHI and PvuII in the vector of pEBVhis [Invitrogen] .
- the resulting plasmid, designated pEBVhisT7N was transfected into 293 cells and selected with Hygromycin at a concentration of 400 ⁇ g/ml. Each positive clone is analyzed for the presence of T7 Pol by its ability to produce expression of T7-LacZ or T7- rep/cap in cells transfected with these plasmids.
- the plasmid pTMl [B. Moss et al, Nature. 348:91-92 (1990)], designed for expressing genes under control of the T7 promoter/EMCV UTR (untranslated region of encephalomyocarditis) , was used as the vector for expressing AAV rep/cap.
- the entire coding sequence of rep/cap was separated into two portions by the unique Sad site and subcloned into the pTMl plasmid as described below.
- N-rep the left end of the rep sequence (N-rep) was first amplified by PCR.
- the sequence of the upper primer was SEQ ID NO: 2: TATTTAAGCCCGAGTGAGCT. (from position of 255 to 274) which introduced a nucleotide substitution A->T at position 274 (underlined) .
- a Sad site was then generated to permit the cloning of N-rep into pTMl and in-frame expression of Rep protein from the EMCV UTR preferred initiation site (within the Ncol site) .
- the PCR product (739 bp in length) was directly cloned into pCR2.1 vector (Invitrogen) and named pCR-N-rep.
- the pTM-1 plasmid was digested with Sad and Stu I restriction enzymes and ligated with a 3.7 kb SacI/SnaBI fragment from psub201 [Samulski et al, J. Virol. ⁇ .51:3096-3101 (1987)] containing the right end of the AAV genome (without ITR sequence), i.e., the c- terminal portion of rep and full-length cap sequence.
- This T7 promoter-driven rep/cap construct is named pT7-c- rep/cap.
- the first 535 bp sequence of rep was removed from the pCR-N-Rep plasmid by Sad digestion and subcloned into pT7-C-rep/cap, which has similarly been digested with Sad and subjected to alkaline phosphatase treatment to prevent self-ligation of the vector.
- the final construct was named pT7 rep/cap which contains the full length coding sequence of rep/cap downstream of T7 promoter/EMCV UTR, followed by the T7 terminating sequence.
- Adenovirus pAd.link is a construct similar to pAd.CMV. link, a plasmid containing the adenoviral sequences 0 to 16 map units deleted of Ela and Elb as described in the other adenovirus vectors into which a CMV promoter-polylinker cassette was cloned and described in X. Ye et al, J. Biol. Chem.. 221:3639-3646 (1996). However, pAd.link contains no CMV promoter or polyA tail sequence.
- the entire region including the T7 promoter, EMCV UTR, rep/cap and T7 terminating sequence was excised from pT7 rep/cap by digestion with Clal and EagI, and then subcloned into the adenoviral sequences of pAd.link, which had previously been subjected to Clal/Sail digestion, after filling in the sticky ends of EagI and Sail by Klenow polymerase.
- the resulting plasmid is designated pAd.T7 rep/cap.
- the pAd.T7 rep/cap is co-transfected with the Clal linearized Ad.del327 backbone DNA into 293 cell for the generation of T7 rep/cap adenovirus.
- Example 4 - Cell Line Expressing rep/cap
- a cell line stably transfected with pT7 rep/cap is established by transfection of pMTCB6+ into 293 cell at ratio of 10:1 and selected with Geneticin. Each clone is analyzed for the presence of rep protein by transfection with T7 Pol expressing plasmid.
- Example 5 Production of Recombinant AAV Hybrid Vector Plasmid pAV.CMVLacZ serves as a template for rAAV to be replicated and packaged in the presence of AAV non-structural and capsid proteins.
- Plasmid AV.CMVLacZ is a rAAV cassette in which rep and cap genes are replaced with a minigene expressing ⁇ -galactosidase from a CMV promoter.
- the linear arrangement of AV.CMV acZ includes: (a) the 5 1 AAV ITR (bp 1-173) obtained by PCR using pAV2 [C. A. Laughlin et al, Gene. 23: 65-73 (1983)] as template [nucleotide numbers 365-538 of SEQ ID NO:l];
- E. coli beta-galactosidase cDNA (nucleotide numbers 1356 - 4827 of SEQ ID N0:1), (e) an SV40 polyadenylation signal (a 237
- Bglll fragment (nucleotide numbers 5053 - 5221 of SEQ ID N0:l) .
- the LacZ gene can be replaced with a desired therapeutic or other transgene for the purpose of generating new rAAV. See, Fig. 4.
- the sequence including CMV directed LacZ reporter cassette in between two AAV ITR sequences is excised from pAV.CMV.LacZ by PvuII digestion. This fragment is ligated with the EcoRV treated pAd.link to generate the plasmid pAd.AV.CMVLacZ.
- This plasmid is co-transfected with Clal linearized Addel327 backbone DNA to generate an adeno-rAAV hybrid virus.
- Example 6 Cell line containing rescuable. integrated rAAV template
- 293 cells are transfected/infected with pAV.CMVLacZ/rAAV Ad hybrid virus to generate cell line that has incorporated rAAV, as determined by analysis of the geno ic DNA by Southern blot. The clone is examined for the rescue of rAAV template by transfection/infection with rep/cap expressing constructs.
- CAAATCAAAG AACTGCTCCT CAGTGGATGT TGCCTTTACT TCTAGGCCTG TACGGAAGTG 1320
- TCCAGTTCCG TTTATCCGGG CAAACCATCG AAGTGACCAG CGAATACCTG TTCCGTCATA 3420
- AAACCTTATT TATCAGCCGG AAAACCTACC GGATTGATGG TAGTGGTCAA ATGGCGATTA 4080
- CTTCTCGCTT CCGGCGGCAT CGGGATGCCC GCGTTGCAGG CCATGCTGTC CAGGCAGGTA 8100
- AAACTCTCAA GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC 10080
- CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC 10200
- MOLECULE TYPE other nucleic acid
- SEQUENCE DESCRIPTION SEQ ID NO:2: TATTTAAGCC CGAGTGAGCT 20
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002264482A CA2264482A1 (fr) | 1996-09-06 | 1997-09-04 | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
EP97939829A EP0931158A1 (fr) | 1996-09-06 | 1997-09-04 | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
AU41833/97A AU722624B2 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
IL12878097A IL128780A0 (en) | 1996-09-06 | 1997-09-04 | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase |
JP10512963A JP2001500015A (ja) | 1996-09-06 | 1997-09-04 | T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2469996P | 1996-09-06 | 1996-09-06 | |
US60/024,699 | 1996-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998010088A1 true WO1998010088A1 (fr) | 1998-03-12 |
Family
ID=21821933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/015716 WO1998010088A1 (fr) | 1996-09-06 | 1997-09-04 | Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0931158A1 (fr) |
JP (1) | JP2001500015A (fr) |
AU (1) | AU722624B2 (fr) |
CA (1) | CA2264482A1 (fr) |
IL (1) | IL128780A0 (fr) |
WO (1) | WO1998010088A1 (fr) |
Cited By (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000015821A1 (fr) * | 1998-09-11 | 2000-03-23 | The Regents Of The University Of California | Adenovirus recombinant pouvant accomplir une expression specifique du tissu cardiaque |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6485966B2 (en) | 1999-03-18 | 2002-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2003046124A2 (fr) | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Sequences d'acides nucleiques et d'acides amines d'adenovirus simiens, vecteurs les contenant et procedes d'utilisation associes |
WO2003078453A1 (fr) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants de la proteine p4 de haemophilus influenzae non typable a activite enzymatique reduite |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US7198951B2 (en) | 2001-12-17 | 2007-04-03 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
US7282199B2 (en) | 2001-12-17 | 2007-10-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
EP1925626A1 (fr) | 2003-07-21 | 2008-05-28 | Transgene S.A. | Nouvelles cytokines multifonctionnelles |
EP1944043A1 (fr) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation. |
EP2116605A2 (fr) | 2004-06-17 | 2009-11-11 | Wyeth | Plasmide doté de trois unités transcriptionnelles complètes et compositions immunogènes pour induire une réponse immunitaire au VIH |
EP2123306A1 (fr) | 2004-12-03 | 2009-11-25 | Fondazione Telethon | Utilisation d'une protéine de leurre qui interfère avec la voie de signalisation Hedgehog pour la fabrication d'un médicament pour empêcher, inhiber, et/ou inverser les maladies oculaires associées à la néovascularisation oculaire |
WO2010051367A1 (fr) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations |
WO2010138675A1 (fr) | 2009-05-29 | 2010-12-02 | The Trustees Of The University Of Pennsylvania | Adénovirus simien 41 et ses utilisations |
EP2292780A2 (fr) | 2003-09-30 | 2011-03-09 | The Trustees of the University of Pennsylvania | Variantes des virus associes aux adenovirus (AAV), sequences, vecteurs les contenant, et leur utilisation |
WO2011053998A2 (fr) * | 2009-11-02 | 2011-05-05 | The Salk Institute For Biological Studies | Ciblage d'enzymes de modification pour l'évolution de protéines |
EP2325298A2 (fr) | 2008-03-04 | 2011-05-25 | The Trustees of The University of Pennsylvania | Adenovirus de singe SAdV-36, -42.1, -42.2, AND -44 et leur utilisation |
EP2338900A1 (fr) | 2001-11-13 | 2011-06-29 | The Trustees of The University of Pennsylvania | Procédé pour détecter et/ou identifier les séquences de virus adéno-associé (AAV) et isolation des nouvelles séquences identifiées avec celui-ci |
EP2357010A1 (fr) | 2005-04-07 | 2011-08-17 | The Trustees of The University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur AAV |
WO2011133890A1 (fr) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Vecteurs aav ciblant le système nerveux central et leurs procédés d'utilisation |
WO2012040550A1 (fr) | 2010-09-26 | 2012-03-29 | Da Yu Enterprises, L.L.C. | Procédé de production macromoléculaire recombinante |
WO2012071318A2 (fr) | 2010-11-23 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens de la sous-famille e a1321, a1325, a1295, a1309, a1316 et a1322 et utilisations de ceux-ci |
EP2463362A1 (fr) | 2007-11-28 | 2012-06-13 | The Trustees of The University of Pennsylvania | Adénovirus SAdv-31 de la sous-famille C des simiens et ses utilisations |
WO2012076715A1 (fr) | 2010-12-09 | 2012-06-14 | Institut Pasteur | Procédé à base de mgmt permettant d'obtenir une expression élevée de protéines recombinées |
WO2012112832A1 (fr) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions et procédés pour modifier une spécificité tissulaire et améliorer le transfert d'un gène induit par aav9 |
US8303567B2 (en) | 2003-09-26 | 2012-11-06 | The Trustees Of The University Of Pennsylvania | Method for delivering a macromolecular complex to muscle cells |
WO2012156535A1 (fr) | 2011-05-19 | 2012-11-22 | Fundación Progreso Y Salud | Système tet-on lentiviral à double promoteur très inductible |
WO2013043720A1 (fr) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Régulation de canaux sodiques par des protéines plunc |
WO2013083847A2 (fr) | 2011-12-09 | 2013-06-13 | Institut Pasteur | Immunoessai de dépistage multiplex |
US8556842B2 (en) | 2004-09-30 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Perfusion circuit and use therein in targeted delivery of macromolecules |
WO2013158879A1 (fr) | 2012-04-18 | 2013-10-24 | The Children's Hospital Of Philadelphia | Composition et procédés pour un transfert génique hautement efficace à l'aide de variants de capside aav |
WO2013173702A2 (fr) | 2012-05-18 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens de la sous-famille e a1302, a1320, a1331 et a1337 et leurs utilisations |
US8632995B2 (en) | 2006-07-27 | 2014-01-21 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
WO2014066443A1 (fr) | 2012-10-23 | 2014-05-01 | Emory University | Conjugués de gm-csf et d'il-4, compositions et procédés associés |
WO2014068072A1 (fr) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, évaluation et traitement de la thrombocytémie essentielle associée à une résistance aux inhibiteurs de jak2 |
WO2015164786A1 (fr) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Vecteurs de virus adéno-associés recombinants utiles pour réduire une immunité contre des produits transgéniques |
WO2015168666A2 (fr) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Vecteurs aav pour thérapie génique de la rétine et du snc |
WO2016054557A1 (fr) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Nouveaux vecteurs aav identifiés au moyen de banques à efficacité élevée |
WO2016065001A1 (fr) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Variants de vaa recombinants et leurs utilisations |
WO2016122791A1 (fr) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Système de délivrance de gènes sous-pial spinal |
WO2016130589A2 (fr) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Variant d'arni |
WO2016130591A2 (fr) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Administration améliorée de particules virales au striatum et au cortex |
WO2016131945A1 (fr) | 2015-02-20 | 2016-08-25 | Transgene Sa | Produit de combinaison modulateur de l'autophagie |
WO2016145217A1 (fr) | 2015-03-10 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Constructions de vecteur viral adéno-associé glut1 de recombinaison et procédés associés permettant de restaurer l'expression de glut1 |
WO2016164609A2 (fr) | 2015-04-08 | 2016-10-13 | Genzyme Corporation | Production de vecteurs adéno-associés surdimensionnés |
WO2016172155A1 (fr) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation de l'expression d'un transgène du vecteur aav |
WO2016186772A2 (fr) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Édition génique de mutations introniques profondes |
US9523084B2 (en) | 2012-11-08 | 2016-12-20 | Centre National De La Recherche Scientifique (Cnrs) | Phosphodeoxyribosyl transferase mutant enzymes and uses thereof |
WO2016210170A1 (fr) | 2015-06-23 | 2016-12-29 | The Children's Hospital Of Philadelphia | Facteur ix modifié, et compositions, méthodes et utilisations pour un transfert de gènes dans des cellules, des organes et des tissus |
EP3128010A1 (fr) | 2007-11-28 | 2017-02-08 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens sadv-30 de la sous-famille e et leurs utilisations |
WO2017070525A1 (fr) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Procédés et compositions pour le traitement du déséquilibre métabolique dans une maladie neurodégénérative |
WO2017075335A1 (fr) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Expression régulable au moyen d'un virus adéno-associé (vaa) |
WO2017096164A1 (fr) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Nouvelles capsides du virus adéno-associé (aav) recombinant offrant un tropisme amélioré des muscles squelettiques humains |
WO2017139643A1 (fr) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Agents thérapeutiques à base de micro-arn anti-angiogéniques pour l'inhibition de la néovascularisation cornéenne |
WO2017143100A1 (fr) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Nouveaux capsides de virus adéno-associés de recombinaison résistants à des anticorps neutralisants humains pré-existants |
WO2017147128A1 (fr) | 2016-02-22 | 2017-08-31 | The University Of North Carolina At Chapel Hill | Inhibiteurs peptidiques de canaux calciques |
WO2017191147A1 (fr) | 2016-05-04 | 2017-11-09 | Transgene Sa | Polythérapie avec un ligand de tlr9 cpg |
WO2017194912A1 (fr) | 2016-05-09 | 2017-11-16 | Cambridge Enterprise Limited | Traitement de troubles médiés par le complément |
WO2017216301A1 (fr) | 2016-06-16 | 2017-12-21 | Charité Berlin | Vecteurs d'expression de neuropeptides et méthodes de traitement de l'épilepsie |
WO2018002081A1 (fr) | 2016-06-27 | 2018-01-04 | Aicuris Anti-Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
WO2018009553A1 (fr) | 2016-07-05 | 2018-01-11 | University Of Massachusetts | Administration de gène à médiation par aav2 de sfasl comme thérapie neuroprotectrice dans le glaucome |
WO2018009894A1 (fr) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation |
WO2018022608A2 (fr) | 2016-07-26 | 2018-02-01 | Biomarin Pharmaceutical Inc. | Nouvelles protéines de capside de virus adéno-associés |
US9890365B2 (en) | 2014-03-09 | 2018-02-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
WO2018035059A1 (fr) | 2016-08-15 | 2018-02-22 | Genzyme Corporation | Méthodes de détection d'aav |
WO2018049261A1 (fr) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Virus oncolytique exprimant des modulateurs du point de contrôle immunitaire |
WO2018057855A1 (fr) | 2016-09-22 | 2018-03-29 | University Of Massachusetts | Traitement vaa de la maladie de huntington |
WO2018060288A1 (fr) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions et méthodes de traitement d'une infection par hpv persistante |
WO2018069316A2 (fr) | 2016-10-10 | 2018-04-19 | Transgene Sa | Polythérapie à base d'un produit immunothérapeutique et de modulateurs de mdsc |
WO2018091680A1 (fr) | 2016-11-18 | 2018-05-24 | Transgene Sa | Vecteurs oncolytiques à base de la variole bovine |
WO2018104911A1 (fr) | 2016-12-09 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Polypeptides et polynucléotides d'adénovirus |
WO2018122088A1 (fr) | 2016-12-28 | 2018-07-05 | Transgene Sa | Virus oncolytiques et molécules thérapeutiques |
WO2018204694A1 (fr) | 2017-05-03 | 2018-11-08 | Biomarin Pharmaceutical Inc. | Lentivirus améliorés pour la transduction de cellules souches hématopoïétiques |
US10137176B2 (en) | 2013-03-15 | 2018-11-27 | The Trustee Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
WO2018232017A1 (fr) | 2017-06-13 | 2018-12-20 | Flagship Pioneering, Inc. | Compositions comprenant des curons et leurs utilisations |
WO2019020543A1 (fr) | 2017-07-28 | 2019-01-31 | Transgene Sa | Virus oncolytiques exprimant des agents ciblant des modulateurs immunitaires métaboliques |
WO2019028306A2 (fr) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions et procédés permettant l'administration de virus adéno-associés |
WO2019060726A1 (fr) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant d'arni |
WO2019079240A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
US10335466B2 (en) | 2014-11-05 | 2019-07-02 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of parkinson's disease |
WO2019173434A1 (fr) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Génomes aav partiels auto-complémentaires fabriqués par des cellules d'insectes |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
EP3539568A1 (fr) | 2011-11-22 | 2019-09-18 | The Children's Hospital of Philadelphia | Vecteurs de virus pour administration transgène hautement efficace |
WO2019191701A1 (fr) | 2018-03-30 | 2019-10-03 | The Board Of Trustees Of Leland Stanford Junior University | Nouvelles capsides du virus adéno-associé recombinant présentant un tropisme pancréatique humain amélioré |
EP3552615A1 (fr) | 2014-07-16 | 2019-10-16 | Transgene SA | Virus oncolytique pour l'expression de modulateurs de point de contrôle immunitaire |
WO2019210137A1 (fr) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Procédés de mesure de la puissance de vecteurs viraux aadc |
WO2019210269A1 (fr) | 2018-04-27 | 2019-10-31 | University Of Massachusetts | Capsides de vaa identifiés par la sélection d'une bibliothèque in vivo |
WO2019217582A1 (fr) | 2018-05-08 | 2019-11-14 | Rutgers, The State University Of New Jersey | Protéines de polymérisation de lieur-laminine compatibles avec aav |
WO2019222136A2 (fr) | 2018-05-14 | 2019-11-21 | Biomarin Pharmaceutical Inc. | Nouveaux vecteurs viraux adéno-associés ciblant le foie |
WO2019222329A1 (fr) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration de vaa |
WO2019222441A1 (fr) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Sérotypes de vaa pour l'administration de charge utile spécifique au cerveau |
WO2019222444A2 (fr) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Évolution dirigée |
WO2019222328A1 (fr) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions et méthodes pour le traitement de la maladie de parkinson |
WO2019239311A1 (fr) | 2018-06-12 | 2019-12-19 | Glaxosmithkline Biologicals Sa | Polynucléotides et polypeptides d'adénovirus |
WO2020010042A1 (fr) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique et de troubles associés à la moelle épinière |
WO2020023612A1 (fr) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systèmes et méthodes de production de formulations de thérapie génique |
WO2020028816A1 (fr) | 2018-08-03 | 2020-02-06 | Genzyme Corporation | Variante d'arni contre l'alpha-synucléine |
US10570395B2 (en) | 2014-11-14 | 2020-02-25 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
EP3613440A1 (fr) | 2013-07-22 | 2020-02-26 | The Children's Hospital of Philadelphia | Compositions et variants de virus adéno-associés et procédés et utilisations pour un transfert de gènes dans des cellules, des organes et des tissus |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2020072849A1 (fr) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Procédés de mesure du titre et de la puissance de particules de vecteur viral |
WO2020072683A1 (fr) | 2018-10-02 | 2020-04-09 | Voyager Therapeutics, Inc. | Redirection de tropisme de capsides aav |
WO2020077165A1 (fr) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration d'aav |
WO2020086893A1 (fr) | 2018-10-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Procédés d'analyse d'une composition de protéines de capside virale |
WO2020112967A1 (fr) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation de sptlc1 par l'intermédiaire de vecteurs adéno-associés recombinés |
WO2020136232A1 (fr) | 2018-12-28 | 2020-07-02 | Transgene Sa | Protéine m2 à propriété immunosuppressive |
WO2020150556A1 (fr) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Procédés et systèmes de fabrication de particules aav |
WO2020172537A1 (fr) | 2019-02-22 | 2020-08-27 | University Of Massachusetts | Thérapie génique avec oxr1 |
WO2020190363A1 (fr) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Contrôle de la fixation de l'azote dans les bactéries rhizobium s'associant à des céréales |
WO2020223274A1 (fr) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | Système et procédé pour la production de cellules d'insectes infectées par baculovirus (ceib) dans les bioréacteurs |
WO2020227515A1 (fr) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines |
WO2020232044A1 (fr) | 2019-05-14 | 2020-11-19 | Biomarin Pharmaceutical Inc. | Méthodes de redosage de vecteurs de thérapie génique |
WO2021021674A1 (fr) | 2019-07-26 | 2021-02-04 | Akouos, Inc. | Méthodes de traitement de la perte auditive à l'aide d'une protéine cible sécrétée |
US10920244B2 (en) | 2009-04-30 | 2021-02-16 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
US10919814B2 (en) | 2015-07-13 | 2021-02-16 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
WO2021030125A1 (fr) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs |
WO2021041485A1 (fr) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Expression contrôlée de protéines virales |
WO2021046155A1 (fr) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Édition vectorisée d'acides nucléiques pour corriger des mutations manifestes |
WO2021050970A1 (fr) | 2019-09-13 | 2021-03-18 | Rutgers, The State University Of New Jersey | Protéines de polymérisation de lieur-laminine compatibles avec aav |
WO2021062164A1 (fr) | 2019-09-27 | 2021-04-01 | Biomarin Pharmaceutical Inc. | Caractérisation de particules virales de thérapie génique à l'aide de technologies de chromatographie d'exclusion stérique et de diffusion de lumière multi-angle |
US10973929B2 (en) | 2016-02-03 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type I |
WO2021155137A1 (fr) | 2020-01-29 | 2021-08-05 | Genzyme Corporation | Protéines de capside de virus adéno-associés modifiés pour thérapie génique oculaire et leurs procédés d'utilisation |
WO2021168362A1 (fr) | 2020-02-21 | 2021-08-26 | Akouos, Inc. | Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain |
WO2021202651A1 (fr) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection de tropisme de capsides de vaa |
WO2021202494A1 (fr) | 2020-03-31 | 2021-10-07 | University Of Massachusetts | Variants capsidiques de vaa et leurs utilisations |
WO2021207592A1 (fr) | 2020-04-09 | 2021-10-14 | 4Mvac Llc | Utilisation de vecteurs viraux pour la production de vaccins contre le coronavirus |
WO2021211753A1 (fr) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Composés de liaison à la protéine tau |
WO2021214443A1 (fr) | 2020-04-20 | 2021-10-28 | Synpromics Limited | Séquences d'acides nucléiques régulatrices |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
WO2021230987A1 (fr) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection de tropisme de capsides de vaa |
WO2021231538A2 (fr) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions et méthodes de traitement de perte auditive associée à kcnq4 |
WO2021231567A2 (fr) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions et méthodes pour traiter une perte auditive associée à slc26a4 |
WO2021247995A2 (fr) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la douleur neuropathique |
WO2022013221A1 (fr) | 2020-07-13 | 2022-01-20 | Transgene | Traitement de la dépression immunitaire |
WO2022032153A1 (fr) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs |
WO2022032140A2 (fr) | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Protéines de ciblage des vésicules et leurs utilisations |
EP3957331A1 (fr) | 2016-03-03 | 2022-02-23 | University Of Massachusetts | Adn double hélice linéaire à extrémité fermée pour transfert de gène non viral |
WO2022049385A1 (fr) | 2020-09-04 | 2022-03-10 | Asklepios Biopharmaceutical, Inc. | Séquences d'acides nucléiques régulatrices |
WO2022051555A2 (fr) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Constructions de phosphatase alcaline solubles et vecteurs d'expression comprenant un polynucléotide codant pour des constructions de phosphatase alcaline solubles |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2022094461A1 (fr) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Méthode d'enrichissement d'un virus adéno-associé |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2022119839A1 (fr) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Constructions d'anticorps anti-vegf et procédés associés pour le traitement de symptômes associés au neurinome de l'acoustique |
WO2022140560A1 (fr) | 2020-12-23 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | Assemblage in vitro de capsides d'anellovirus renfermant de l'arn |
WO2022147480A1 (fr) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique |
WO2022146839A1 (fr) | 2020-12-29 | 2022-07-07 | Akouos, Inc. | Compositions et méthodes pour traiter une perte auditive et/ou une perte de la vision associées à clrn1 |
EP4039813A1 (fr) | 2013-07-12 | 2022-08-10 | The Children's Hospital of Philadelphia | Vecteur aav et analyse pour anticorps de neutralisation anti-aav (virus adéno-associé) |
WO2022187473A2 (fr) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Expression contrôlée de protéines virales |
WO2022187548A1 (fr) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Expression régulée de protéines virales |
WO2022214632A1 (fr) | 2021-04-07 | 2022-10-13 | Neoplants Sas | Compositions et procédés d'assainissement d'air intérieur |
US11479516B2 (en) | 2015-10-05 | 2022-10-25 | Massachusetts Institute Of Technology | Nitrogen fixation using refactored NIF clusters |
WO2022235586A1 (fr) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Procédés de génération de cellules endothéliales cornéennes matures |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
US11525139B2 (en) | 2016-08-23 | 2022-12-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11565979B2 (en) | 2017-01-12 | 2023-01-31 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
WO2023019203A1 (fr) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Systèmes inductibles pour modifier l'expression génique dans des cellules hypoimmunogènes |
WO2023034980A1 (fr) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034996A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034994A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034990A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034997A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034989A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2023044483A2 (fr) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement du cancer positif her2 |
WO2023056329A1 (fr) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions et méthodes de traitement de perte auditive associée à kcnq4 |
EP4169576A1 (fr) | 2018-03-23 | 2023-04-26 | University of Massachusetts | Therapeutique genique pour le traitement de troubles osseux |
WO2023081648A1 (fr) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Variants capsidiques de vaa et utilisations associées |
WO2023091948A1 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Variants de capsides d'aav et leurs utilisations |
WO2023107188A1 (fr) | 2021-12-10 | 2023-06-15 | Massachusetts Institute Of Technology | Prédiction, biosynthèse et intégration en tant que biodétecteurs de molécules portant des signes d'absorption de la lumière uniques, et de leur détection à distance sur le terrain au moyen de caméras multispectrales ou hyperspectrales |
WO2023111580A1 (fr) | 2021-12-16 | 2023-06-22 | University Of Dundee | Dégradation ciblée de l'alpha-synucléine |
US11697801B2 (en) | 2017-12-19 | 2023-07-11 | Akouos, Inc. | AAV-mediated delivery of therapeutic antibodies to the inner ear |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2023147374A2 (fr) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Système d'expression de baculovirus |
WO2023150142A1 (fr) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Constructions d'anticorps anti-vegf et méthodes associées pour le traitement de symptômes associés au schwannome vestibulaire |
WO2023154693A1 (fr) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Variants de capside d'aav et leurs utilisations |
WO2023152504A1 (fr) | 2022-02-10 | 2023-08-17 | University Of Dundee | Système de phosphatase dirigé par affinité pour la déphosphorylation ciblée de protéines |
US11739346B2 (en) | 2017-04-05 | 2023-08-29 | University Of Massachusetts | Minigene therapy |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
US11759506B2 (en) | 2017-06-15 | 2023-09-19 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of Parkinson's disease |
US11773407B2 (en) | 2017-06-26 | 2023-10-03 | Arizona Board Of Regents On Behalf Of Arizona State University | CRISPR logic circuits for safer and controllable gene therapies |
WO2023196862A1 (fr) | 2022-04-06 | 2023-10-12 | Genzyme Corporation | Thérapie génique ciblée pour la dystrophie myotonique dm-1 |
WO2023200843A1 (fr) | 2022-04-12 | 2023-10-19 | The Broad Institute, Inc. | Compositions et méthodes de criblage d'éléments régulateurs cis |
WO2023201273A1 (fr) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Dosage de cellules dendritiques pour l'immunogénicité innée d'agents de thérapie génique |
WO2023201272A1 (fr) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Utilisation de modulateurs irak4 pour la thérapie génique |
WO2023201274A1 (fr) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Utilisation d'un modulateur irak4 pour la thérapie génique |
WO2023213764A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf |
WO2023213763A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus codant pour un agent de liaison comprenant un sdab anti-pd-l1 |
WO2023220729A2 (fr) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn à double brin et procédés associés |
WO2023235791A1 (fr) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Variants de capside de vaa et leurs utilisations |
WO2024003353A1 (fr) | 2022-07-01 | 2024-01-04 | Transgene | Protéine de fusion comprenant une protéine d tensioactive et un élément de la tnfsf |
WO2024006741A1 (fr) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Variants de capside d'aav et leurs utilisations |
WO2024009280A1 (fr) | 2022-07-08 | 2024-01-11 | Baylor College Of Medicine | Inhibiteurs de réponse au stress intégrés et leurs méthodes d'utilisation |
WO2024011112A1 (fr) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Variants de capside d'aav et leurs utilisations |
US11884925B2 (en) | 2018-11-08 | 2024-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Synthetic immunomodulation with a CRISPR super-repressor in vivo |
US11890329B2 (en) | 2017-07-06 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
WO2024054983A1 (fr) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Expression controlée de protéines virales |
WO2024059739A1 (fr) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Composés de liaison à la protéine tau |
WO2024064863A2 (fr) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Traitement de la cardiomyopathie arythmogène avec des vecteurs de thérapie génique aav |
WO2024064856A1 (fr) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Traitement de la cardiomyopathie au moyen de vecteurs de thérapie génique aav |
US11946162B2 (en) | 2012-11-01 | 2024-04-02 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
EP4345106A1 (fr) | 2022-09-30 | 2024-04-03 | Charité - Universitätsmedizin Berlin | Vecteurs de thérapie génique pour l'expression de variants de préprodyrphine pour le traitement de l'épilepsie |
WO2024069010A1 (fr) | 2022-09-30 | 2024-04-04 | Charité - Universitätsmedizin Berlin | Vecteurs de thérapie génique pour l'expression de variants de préprodynorphine pour le traitement de l'épilepsie |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241486A1 (fr) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Régions 5' non traduites (5'utr) modifiées pour la production d'aav |
SG11202103425YA (en) | 2018-10-05 | 2021-05-28 | Voyager Therapeutics Inc | Engineered nucleic acid constructs encoding aav production proteins |
JP2022505106A (ja) | 2018-10-15 | 2022-01-14 | ボイジャー セラピューティクス インコーポレイテッド | バキュロウイルス/Sf9システムにおけるrAAVの大規模産生のための発現ベクター |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000905A1 (fr) * | 1989-07-07 | 1991-01-24 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Systeme rapide, versatile et simple d'expression de genes dans des cellules eukaryotiques |
WO1994013788A1 (fr) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Systeme porteur viral de recombinaison |
WO1994026911A1 (fr) * | 1993-05-14 | 1994-11-24 | Ohio University Edison Animal Biotechnology Institute | Systeme d'expression genique dans lequel une preliaison d'arn polymerase a l'adn est utilisee |
WO1995013392A1 (fr) * | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe |
WO1995013365A1 (fr) * | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Production de titres eleves de vecteurs d'aav recombinants |
WO1995014771A1 (fr) * | 1993-11-24 | 1995-06-01 | GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health | Systemes vectoriels destines a la generation de particules d'un virus ayant les caracteristiques d'un adenovirus |
WO1996012010A1 (fr) * | 1994-10-13 | 1996-04-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet |
WO1996013598A2 (fr) * | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Virus hybride adenovirus-aav et ses procedes d'utilisation |
WO1996014061A1 (fr) * | 1994-11-03 | 1996-05-17 | Cell Genesys, Inc. | Nouveaux vecteurs adenoviraux, lignees cellulaires d'encapsidation, adenovirus recombines et procedes |
WO1996017947A1 (fr) * | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants |
WO1997000947A1 (fr) * | 1995-06-23 | 1997-01-09 | Rhone-Poulenc Rorer S.A. | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
-
1997
- 1997-09-04 EP EP97939829A patent/EP0931158A1/fr not_active Withdrawn
- 1997-09-04 IL IL12878097A patent/IL128780A0/xx unknown
- 1997-09-04 WO PCT/US1997/015716 patent/WO1998010088A1/fr not_active Application Discontinuation
- 1997-09-04 AU AU41833/97A patent/AU722624B2/en not_active Ceased
- 1997-09-04 CA CA002264482A patent/CA2264482A1/fr not_active Abandoned
- 1997-09-04 JP JP10512963A patent/JP2001500015A/ja active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991000905A1 (fr) * | 1989-07-07 | 1991-01-24 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Systeme rapide, versatile et simple d'expression de genes dans des cellules eukaryotiques |
WO1994013788A1 (fr) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Systeme porteur viral de recombinaison |
WO1994026911A1 (fr) * | 1993-05-14 | 1994-11-24 | Ohio University Edison Animal Biotechnology Institute | Systeme d'expression genique dans lequel une preliaison d'arn polymerase a l'adn est utilisee |
WO1995013392A1 (fr) * | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe |
WO1995013365A1 (fr) * | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Production de titres eleves de vecteurs d'aav recombinants |
WO1995014771A1 (fr) * | 1993-11-24 | 1995-06-01 | GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health | Systemes vectoriels destines a la generation de particules d'un virus ayant les caracteristiques d'un adenovirus |
WO1996012010A1 (fr) * | 1994-10-13 | 1996-04-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet |
WO1996013598A2 (fr) * | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Virus hybride adenovirus-aav et ses procedes d'utilisation |
WO1996014061A1 (fr) * | 1994-11-03 | 1996-05-17 | Cell Genesys, Inc. | Nouveaux vecteurs adenoviraux, lignees cellulaires d'encapsidation, adenovirus recombines et procedes |
WO1996017947A1 (fr) * | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants |
WO1997000947A1 (fr) * | 1995-06-23 | 1997-01-09 | Rhone-Poulenc Rorer S.A. | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
Non-Patent Citations (6)
Title |
---|
A. LIEBER ET AL.: "High level gene expression in mammalian cells by a nuclear T7-phage RNA polymerase", NUCLEIC ACIDS RESEARCH, vol. 17, no. 21, - 1989, IRL PRESS LIMITED,OXFORD,ENGLAND, pages 8485 - 8493, XP002052543 * |
CLARK K R ET AL: "CELL LINES FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS", HUMAN GENE THERAPY, vol. 6, no. 10, 1 October 1995 (1995-10-01), pages 1329 - 1341, XP000569718 * |
ELROY-STEIN O ET AL: "CYTOPLASMIC EXPRESSION SYSTEM BASED ON CONSTITUTIVE SYNTHESIS OF BACTERIOPHAGE T7 POLYMERASE IN MAMMALIAN CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 17, 1 September 1990 (1990-09-01), pages 6743 - 6747, XP000563742 * |
FUERST T R ET AL: "EUKARYOTIC TRANSIENT-EXPRESSION SYSTEM BASED ON RECOMBINANT VACCINIA VIRUS THAT SYNTHESIZES BACTERIOPHAGE T7 RNA POLYMERASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 83, no. 21, 1 November 1986 (1986-11-01), pages 8122 - 8126, XP000563743 * |
KOTIN R M: "PROSPECTS FOR THE USE OF ADENO-ASSOCIATED VIRUS AS A VECTOR FOR HUMAN GENE THERAPY", HUMAN GENE THERAPY, vol. 5, 1994, pages 793 - 801, XP000651491 * |
LEONARD, C. J. ET AL: "Cloning, expression, and partial purification of Rep78: an adeno - associated virus replication protein", VIROLOGY (1994), 200(2), 566-73 CODEN: VIRLAX;ISSN: 0042-6822, 1994, XP002052542 * |
Cited By (325)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6451594B1 (en) | 1998-09-11 | 2002-09-17 | The Regents Of The University Of California | Recombinant adenovirus for tissue specific expression in heart |
WO2000015821A1 (fr) * | 1998-09-11 | 2000-03-23 | The Regents Of The University Of California | Adenovirus recombinant pouvant accomplir une expression specifique du tissu cardiaque |
US8637255B2 (en) | 1998-11-05 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US9163260B2 (en) | 1998-11-05 | 2015-10-20 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US7105345B2 (en) | 1998-11-05 | 2006-09-12 | The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US7186552B2 (en) | 1998-11-05 | 2007-03-06 | The Trustees Of University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US9567607B2 (en) | 1998-11-05 | 2017-02-14 | Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US6485966B2 (en) | 1999-03-18 | 2002-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US7022519B2 (en) | 1999-03-18 | 2006-04-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US11034977B2 (en) | 2001-11-13 | 2021-06-15 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10508286B2 (en) | 2001-11-13 | 2019-12-17 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US8906675B2 (en) | 2001-11-13 | 2014-12-09 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US8524446B2 (en) | 2001-11-13 | 2013-09-03 | The Trustees Of The University Of Pennsylvania | Method for detecting adeno-associated virus |
US11499167B2 (en) | 2001-11-13 | 2022-11-15 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10544432B2 (en) | 2001-11-13 | 2020-01-28 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10526617B2 (en) | 2001-11-13 | 2020-01-07 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11041171B2 (en) | 2001-11-13 | 2021-06-22 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10308958B2 (en) | 2001-11-13 | 2019-06-04 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11377669B2 (en) | 2001-11-13 | 2022-07-05 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US10041090B2 (en) | 2001-11-13 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US9790472B2 (en) | 2001-11-13 | 2017-10-17 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
US11034976B2 (en) | 2001-11-13 | 2021-06-15 | The Trustees Of The University Of Pennsylvania | Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby |
EP2341068A1 (fr) | 2001-11-13 | 2011-07-06 | The Trustees of The University of Pennsylvania | Procédé pour détecter et/ou identifier les séquences de virus adéno-associé (AAV) et isolation des nouvelles séquences identifiées avec celui-ci |
EP2338900A1 (fr) | 2001-11-13 | 2011-06-29 | The Trustees of The University of Pennsylvania | Procédé pour détecter et/ou identifier les séquences de virus adéno-associé (AAV) et isolation des nouvelles séquences identifiées avec celui-ci |
EP2286841A1 (fr) | 2001-11-21 | 2011-02-23 | The Trustees of The University of Pennsylvania | Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation. |
EP3108899A1 (fr) | 2001-11-21 | 2016-12-28 | The Trustees of the University of Pennsylvania | Séquences d'acide aminé et d'acide nucléique adsv1 adénovirus simien, vecteurs les contenant et procédés d'utilisation |
EP2301582A1 (fr) | 2001-11-21 | 2011-03-30 | The Trustees of The University of Pennsylvania | Séquences d'acide aminé et d'acide nucléique d'adénovirus simien, vecteurs les contenant et procédés d'utilisation |
EP1944043A1 (fr) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation. |
WO2003046124A2 (fr) | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Sequences d'acides nucleiques et d'acides amines d'adenovirus simiens, vecteurs les contenant et procedes d'utilisation associes |
EP2573170A2 (fr) | 2001-12-17 | 2013-03-27 | The Trustees of the University of Pennsylvania | Séquences de sérotype 9 de virus adéno-associé, vecteurs les contenant et leurs utilisations |
US7790449B2 (en) | 2001-12-17 | 2010-09-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor |
EP3517134A1 (fr) | 2001-12-17 | 2019-07-31 | The Trustees of the University of Pennsylvania | Séquences de virus adéno-associés de sérotype 8 , vecteurs les contenant et leurs utilisations |
US10301650B2 (en) | 2001-12-17 | 2019-05-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US10266846B2 (en) | 2001-12-17 | 2019-04-23 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US10590435B2 (en) | 2001-12-17 | 2020-03-17 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US11396663B2 (en) | 2001-12-17 | 2022-07-26 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US11390883B2 (en) | 2001-12-17 | 2022-07-19 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US9677089B2 (en) | 2001-12-17 | 2017-06-13 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US8962330B2 (en) | 2001-12-17 | 2015-02-24 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US9587250B2 (en) | 2001-12-17 | 2017-03-07 | Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US7282199B2 (en) | 2001-12-17 | 2007-10-16 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US7198951B2 (en) | 2001-12-17 | 2007-04-03 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 9 sequences, vectors containing same, and uses therefor |
US9493788B2 (en) | 2001-12-17 | 2016-11-15 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US8318480B2 (en) | 2001-12-17 | 2012-11-27 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
US8962332B2 (en) | 2001-12-17 | 2015-02-24 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
EP2359869A2 (fr) | 2001-12-17 | 2011-08-24 | The Trustees of The University of Pennsylvania | Séquences de virus adéno-associés de sérotype 8 , vecteurs les contenant et leurs utilisations |
WO2003078453A1 (fr) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants de la proteine p4 de haemophilus influenzae non typable a activite enzymatique reduite |
EP1925626A1 (fr) | 2003-07-21 | 2008-05-28 | Transgene S.A. | Nouvelles cytokines multifonctionnelles |
EP1944318A1 (fr) | 2003-07-21 | 2008-07-16 | Transgene S.A. | Nouvelles cytokines multifonctionnelles |
US8303567B2 (en) | 2003-09-26 | 2012-11-06 | The Trustees Of The University Of Pennsylvania | Method for delivering a macromolecular complex to muscle cells |
US9283357B2 (en) | 2003-09-26 | 2016-03-15 | The Trustees Of The University Of Pennsylvania | Methods, compositions and apparatus for delivering heterologous molecules to cells |
US8986282B2 (en) | 2003-09-26 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Methods, compositions and apparatus for delivering heterologous molecules to cells |
EP2292780A2 (fr) | 2003-09-30 | 2011-03-09 | The Trustees of the University of Pennsylvania | Variantes des virus associes aux adenovirus (AAV), sequences, vecteurs les contenant, et leur utilisation |
EP2298926A1 (fr) | 2003-09-30 | 2011-03-23 | The Trustees of The University of Pennsylvania | Clades (sous-types) et séquences de Virus Adeno-Associé (AAV), vecteurs les contenant et leurs utilistation |
EP2292779A2 (fr) | 2003-09-30 | 2011-03-09 | The Trustees of the University of Pennsylvania | Variantes des virus associes aux adenovirus (AAV), sequences, vecteurs les contenant, et leur utilisation |
EP2345731A1 (fr) | 2003-09-30 | 2011-07-20 | The Trustees of the University of Pennsylvania | Variantes des virus associés aux adénovirus (AAV), séquences, vecteurs les contenant et leur utilisation |
EP2116605A2 (fr) | 2004-06-17 | 2009-11-11 | Wyeth | Plasmide doté de trois unités transcriptionnelles complètes et compositions immunogènes pour induire une réponse immunitaire au VIH |
US8556842B2 (en) | 2004-09-30 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Perfusion circuit and use therein in targeted delivery of macromolecules |
EP2123306A1 (fr) | 2004-12-03 | 2009-11-25 | Fondazione Telethon | Utilisation d'une protéine de leurre qui interfère avec la voie de signalisation Hedgehog pour la fabrication d'un médicament pour empêcher, inhiber, et/ou inverser les maladies oculaires associées à la néovascularisation oculaire |
EP4282956A2 (fr) | 2005-04-07 | 2023-11-29 | The Trustees of the University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur aav |
EP2357010A1 (fr) | 2005-04-07 | 2011-08-17 | The Trustees of The University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur AAV |
EP3085389A1 (fr) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Procédé d'augmentation de la fonction d'un vecteur aav |
EP4282957A2 (fr) | 2005-04-07 | 2023-11-29 | The Trustees of the University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur aav |
EP2359865A1 (fr) | 2005-04-07 | 2011-08-24 | The Trustees of The University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur AAV |
EP2359866A1 (fr) | 2005-04-07 | 2011-08-24 | The Trustees of The University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur AAV |
EP2359867A1 (fr) | 2005-04-07 | 2011-08-24 | The Trustees of The University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur AAV |
EP2383346A1 (fr) | 2005-04-07 | 2011-11-02 | The Trustees of the University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur AAV |
EP3603676A1 (fr) | 2005-04-07 | 2020-02-05 | The Trustees of the University of Pennsylvania | Procédé d'amélioration de la fonction d'un vecteur aav |
US10301663B2 (en) | 2006-07-27 | 2019-05-28 | Wyeth, Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
US9279000B2 (en) | 2006-07-27 | 2016-03-08 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
US8632995B2 (en) | 2006-07-27 | 2014-01-21 | Wyeth Llc | High-cell density fed-batch fermentation process for producing recombinant protein |
EP3705579A1 (fr) | 2006-07-27 | 2020-09-09 | Wyeth LLC | Procédé de fermentation en lot alimenté a haute densité cellulaire pour obtenir une protéine recombinante |
EP3128010A1 (fr) | 2007-11-28 | 2017-02-08 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens sadv-30 de la sous-famille e et leurs utilisations |
EP2463362A1 (fr) | 2007-11-28 | 2012-06-13 | The Trustees of The University of Pennsylvania | Adénovirus SAdv-31 de la sous-famille C des simiens et ses utilisations |
EP2325298A2 (fr) | 2008-03-04 | 2011-05-25 | The Trustees of The University of Pennsylvania | Adenovirus de singe SAdV-36, -42.1, -42.2, AND -44 et leur utilisation |
WO2010051367A1 (fr) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens sadv-43, -45, -48, -49 et –50 et leurs utilisations |
EP2774985A1 (fr) | 2008-10-31 | 2014-09-10 | The Trustees of The University of Pennsylvania | Adénovirus simien SAdV-43 et son utilisations |
US10920244B2 (en) | 2009-04-30 | 2021-02-16 | The Trustees Of The University Of Pennsylvania | Compositions for targeting conducting airway cells comprising adeno-associated virus constructs |
WO2010138675A1 (fr) | 2009-05-29 | 2010-12-02 | The Trustees Of The University Of Pennsylvania | Adénovirus simien 41 et ses utilisations |
WO2011053998A3 (fr) * | 2009-11-02 | 2011-11-24 | The Salk Institute For Biological Studies | Ciblage d'enzymes de modification pour l'évolution de protéines |
WO2011053998A2 (fr) * | 2009-11-02 | 2011-05-05 | The Salk Institute For Biological Studies | Ciblage d'enzymes de modification pour l'évolution de protéines |
EP3514232A1 (fr) | 2010-04-23 | 2019-07-24 | University of Massachusetts | Vecteurs aav de ciblage du système nerveux central et leurs procédés d'utilisation |
WO2011133890A1 (fr) | 2010-04-23 | 2011-10-27 | University Of Massachusetts | Vecteurs aav ciblant le système nerveux central et leurs procédés d'utilisation |
EP3540055A1 (fr) | 2010-04-23 | 2019-09-18 | University of Massachusetts | Vecteurs aav de ciblage du système nerveux central et leurs procédés d'utilisation |
EP3536781A1 (fr) | 2010-04-23 | 2019-09-11 | University of Massachusetts | Vecteurs aav de ciblage du système nerveux central et leurs procédés d'utilisation |
EP3567106A1 (fr) | 2010-04-23 | 2019-11-13 | University of Massachusetts | Vecteurs aav de ciblage du système nerveux central et leurs procédés d'utilisation |
EP2826860A1 (fr) | 2010-04-23 | 2015-01-21 | The University of Massachusetts | Vecteurs AAV de ciblage du système nerveux central et leurs procédés d'utilisation |
WO2012040550A1 (fr) | 2010-09-26 | 2012-03-29 | Da Yu Enterprises, L.L.C. | Procédé de production macromoléculaire recombinante |
WO2012071318A2 (fr) | 2010-11-23 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens de la sous-famille e a1321, a1325, a1295, a1309, a1316 et a1322 et utilisations de ceux-ci |
WO2012076715A1 (fr) | 2010-12-09 | 2012-06-14 | Institut Pasteur | Procédé à base de mgmt permettant d'obtenir une expression élevée de protéines recombinées |
EP3202897A1 (fr) | 2010-12-09 | 2017-08-09 | Institut Pasteur | Procédé de type mgmt pour obtenir un rendement élevé d'expression de protéine recombinante |
US11766448B2 (en) | 2011-02-17 | 2023-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
US10406173B2 (en) | 2011-02-17 | 2019-09-10 | Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
WO2012112832A1 (fr) | 2011-02-17 | 2012-08-23 | The Trustees Of The University Of Pennsylvania | Compositions et procédés pour modifier une spécificité tissulaire et améliorer le transfert d'un gène induit par aav9 |
US10918658B2 (en) | 2011-02-17 | 2021-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
US9884071B2 (en) | 2011-02-17 | 2018-02-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer |
WO2012156535A1 (fr) | 2011-05-19 | 2012-11-22 | Fundación Progreso Y Salud | Système tet-on lentiviral à double promoteur très inductible |
WO2013043720A1 (fr) | 2011-09-20 | 2013-03-28 | The University Of North Carolina At Chapel Hill | Régulation de canaux sodiques par des protéines plunc |
EP3539568A1 (fr) | 2011-11-22 | 2019-09-18 | The Children's Hospital of Philadelphia | Vecteurs de virus pour administration transgène hautement efficace |
WO2013083847A2 (fr) | 2011-12-09 | 2013-06-13 | Institut Pasteur | Immunoessai de dépistage multiplex |
WO2013158879A1 (fr) | 2012-04-18 | 2013-10-24 | The Children's Hospital Of Philadelphia | Composition et procédés pour un transfert génique hautement efficace à l'aide de variants de capside aav |
WO2013173702A2 (fr) | 2012-05-18 | 2013-11-21 | The Trustees Of The University Of Pennsylvania | Adénovirus simiens de la sous-famille e a1302, a1320, a1331 et a1337 et leurs utilisations |
EP3587455A1 (fr) | 2012-10-23 | 2020-01-01 | Emory University | Conjugués de gm-csf et d'il-4, compositions et procédés associés |
WO2014066443A1 (fr) | 2012-10-23 | 2014-05-01 | Emory University | Conjugués de gm-csf et d'il-4, compositions et procédés associés |
WO2014068072A1 (fr) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, évaluation et traitement de la thrombocytémie essentielle associée à une résistance aux inhibiteurs de jak2 |
US11946162B2 (en) | 2012-11-01 | 2024-04-02 | Massachusetts Institute Of Technology | Directed evolution of synthetic gene cluster |
US9523084B2 (en) | 2012-11-08 | 2016-12-20 | Centre National De La Recherche Scientifique (Cnrs) | Phosphodeoxyribosyl transferase mutant enzymes and uses thereof |
US10137176B2 (en) | 2013-03-15 | 2018-11-27 | The Trustee Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
EP3747998A1 (fr) | 2013-03-15 | 2020-12-09 | The Trustees of the University of Pennsylvania | Compositions pour le traitement de la mpsi |
US10792343B2 (en) | 2013-03-15 | 2020-10-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
EP4039813A1 (fr) | 2013-07-12 | 2022-08-10 | The Children's Hospital of Philadelphia | Vecteur aav et analyse pour anticorps de neutralisation anti-aav (virus adéno-associé) |
EP3613440A1 (fr) | 2013-07-22 | 2020-02-26 | The Children's Hospital of Philadelphia | Compositions et variants de virus adéno-associés et procédés et utilisations pour un transfert de gènes dans des cellules, des organes et des tissus |
US11732246B2 (en) | 2014-03-09 | 2023-08-22 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US10167454B2 (en) | 2014-03-09 | 2019-01-01 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US10781430B2 (en) | 2014-03-09 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US9890365B2 (en) | 2014-03-09 | 2018-02-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
US10626382B2 (en) | 2014-03-09 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency |
WO2015164786A1 (fr) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Vecteurs de virus adéno-associés recombinants utiles pour réduire une immunité contre des produits transgéniques |
WO2015168666A2 (fr) | 2014-05-02 | 2015-11-05 | Genzyme Corporation | Vecteurs aav pour thérapie génique de la rétine et du snc |
US10982228B2 (en) | 2014-05-02 | 2021-04-20 | Genzyme Corporation | AAV vectors for retinal and CNS gene therapy |
EP3913061A1 (fr) | 2014-05-02 | 2021-11-24 | Genzyme Corporation | Vecteurs aav pour thérapie génique de la rétine et du snc |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
EP3552615A1 (fr) | 2014-07-16 | 2019-10-16 | Transgene SA | Virus oncolytique pour l'expression de modulateurs de point de contrôle immunitaire |
EP3795580A1 (fr) | 2014-10-03 | 2021-03-24 | University of Massachusetts | Vecteurs aav identifiés au moyen de banques à efficacité élevée |
WO2016054557A1 (fr) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Nouveaux vecteurs aav identifiés au moyen de banques à efficacité élevée |
WO2016065001A1 (fr) | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Variants de vaa recombinants et leurs utilisations |
US10335466B2 (en) | 2014-11-05 | 2019-07-02 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of parkinson's disease |
US11027000B2 (en) | 2014-11-05 | 2021-06-08 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of Parkinson's disease |
US10570395B2 (en) | 2014-11-14 | 2020-02-25 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11198873B2 (en) | 2014-11-14 | 2021-12-14 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US11542506B2 (en) | 2014-11-14 | 2023-01-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US10920227B2 (en) | 2014-11-14 | 2021-02-16 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2016122791A1 (fr) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Système de délivrance de gènes sous-pial spinal |
EP4023758A1 (fr) | 2015-02-10 | 2022-07-06 | Genzyme Corporation | Administration améliorée de particules virales au striatum et au cortex |
US10450563B2 (en) | 2015-02-10 | 2019-10-22 | Genzyme Corporation | Variant RNAi |
EP4219728A2 (fr) | 2015-02-10 | 2023-08-02 | Genzyme Corporation | Administration améliorée de particules virales au striatum et au cortex |
WO2016130591A2 (fr) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Administration améliorée de particules virales au striatum et au cortex |
US11781137B2 (en) | 2015-02-10 | 2023-10-10 | Genzyme Corporation | Variant RNAi |
WO2016130589A2 (fr) | 2015-02-10 | 2016-08-18 | Genzyme Corporation | Variant d'arni |
US10760079B2 (en) | 2015-02-10 | 2020-09-01 | Genzyme Corporation | Variant RNAi |
WO2016131945A1 (fr) | 2015-02-20 | 2016-08-25 | Transgene Sa | Produit de combinaison modulateur de l'autophagie |
WO2016145217A1 (fr) | 2015-03-10 | 2016-09-15 | The Trustees Of Columbia University In The City Of New York | Constructions de vecteur viral adéno-associé glut1 de recombinaison et procédés associés permettant de restaurer l'expression de glut1 |
WO2016164609A2 (fr) | 2015-04-08 | 2016-10-13 | Genzyme Corporation | Production de vecteurs adéno-associés surdimensionnés |
WO2016172155A1 (fr) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation de l'expression d'un transgène du vecteur aav |
WO2016186772A2 (fr) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Édition génique de mutations introniques profondes |
WO2016210170A1 (fr) | 2015-06-23 | 2016-12-29 | The Children's Hospital Of Philadelphia | Facteur ix modifié, et compositions, méthodes et utilisations pour un transfert de gènes dans des cellules, des organes et des tissus |
US11739032B2 (en) | 2015-07-13 | 2023-08-29 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US10919814B2 (en) | 2015-07-13 | 2021-02-16 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US10934226B2 (en) | 2015-07-13 | 2021-03-02 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US11479516B2 (en) | 2015-10-05 | 2022-10-25 | Massachusetts Institute Of Technology | Nitrogen fixation using refactored NIF clusters |
WO2017070525A1 (fr) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Procédés et compositions pour le traitement du déséquilibre métabolique dans une maladie neurodégénérative |
WO2017075335A1 (fr) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Expression régulable au moyen d'un virus adéno-associé (vaa) |
WO2017096164A1 (fr) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Nouvelles capsides du virus adéno-associé (aav) recombinant offrant un tropisme amélioré des muscles squelettiques humains |
US10973929B2 (en) | 2016-02-03 | 2021-04-13 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type I |
EP4094780A2 (fr) | 2016-02-12 | 2022-11-30 | University of Massachusetts | Thérapeutiques micro-arn anti-angiogéniques pour l'inhibition de la néovascularisation de la cornée |
WO2017139643A1 (fr) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Agents thérapeutiques à base de micro-arn anti-angiogéniques pour l'inhibition de la néovascularisation cornéenne |
WO2017143100A1 (fr) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Nouveaux capsides de virus adéno-associés de recombinaison résistants à des anticorps neutralisants humains pré-existants |
WO2017147128A1 (fr) | 2016-02-22 | 2017-08-31 | The University Of North Carolina At Chapel Hill | Inhibiteurs peptidiques de canaux calciques |
EP3957331A1 (fr) | 2016-03-03 | 2022-02-23 | University Of Massachusetts | Adn double hélice linéaire à extrémité fermée pour transfert de gène non viral |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017191147A1 (fr) | 2016-05-04 | 2017-11-09 | Transgene Sa | Polythérapie avec un ligand de tlr9 cpg |
WO2017194912A1 (fr) | 2016-05-09 | 2017-11-16 | Cambridge Enterprise Limited | Traitement de troubles médiés par le complément |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11193129B2 (en) | 2016-05-18 | 2021-12-07 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
WO2017216301A1 (fr) | 2016-06-16 | 2017-12-21 | Charité Berlin | Vecteurs d'expression de neuropeptides et méthodes de traitement de l'épilepsie |
WO2018002081A1 (fr) | 2016-06-27 | 2018-01-04 | Aicuris Anti-Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
WO2018009553A1 (fr) | 2016-07-05 | 2018-01-11 | University Of Massachusetts | Administration de gène à médiation par aav2 de sfasl comme thérapie neuroprotectrice dans le glaucome |
WO2018009894A1 (fr) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Protéines de liaison au ligand (1) de mort programmée (1) (pd-l1) et leurs procédés d'utilisation |
WO2018022608A2 (fr) | 2016-07-26 | 2018-02-01 | Biomarin Pharmaceutical Inc. | Nouvelles protéines de capside de virus adéno-associés |
US11584780B2 (en) | 2016-07-26 | 2023-02-21 | Biomarin Pharmaceutical Inc. | Adeno-associated virus capsid proteins |
EP3851449A1 (fr) | 2016-08-15 | 2021-07-21 | Genzyme Corporation | Procédés de détection d'aav |
WO2018035059A1 (fr) | 2016-08-15 | 2018-02-22 | Genzyme Corporation | Méthodes de détection d'aav |
US11525139B2 (en) | 2016-08-23 | 2022-12-13 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
US11781145B2 (en) | 2016-08-23 | 2023-10-10 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
EP4219724A2 (fr) | 2016-08-23 | 2023-08-02 | Akouos, Inc. | Compositions et procédés pour traiter une déficience auditive non associée au vieillissement chez un sujet humain |
WO2018049261A1 (fr) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Virus oncolytique exprimant des modulateurs du point de contrôle immunitaire |
WO2018049248A1 (fr) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Virus oncolytique équipé de molécules d'engagement bispécifiques |
WO2018057855A1 (fr) | 2016-09-22 | 2018-03-29 | University Of Massachusetts | Traitement vaa de la maladie de huntington |
WO2018060288A1 (fr) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions et méthodes de traitement d'une infection par hpv persistante |
WO2018069316A2 (fr) | 2016-10-10 | 2018-04-19 | Transgene Sa | Polythérapie à base d'un produit immunothérapeutique et de modulateurs de mdsc |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
US11667890B2 (en) | 2016-10-31 | 2023-06-06 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
WO2018091680A1 (fr) | 2016-11-18 | 2018-05-24 | Transgene Sa | Vecteurs oncolytiques à base de la variole bovine |
WO2018104911A1 (fr) | 2016-12-09 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Polypeptides et polynucléotides d'adénovirus |
WO2018122088A1 (fr) | 2016-12-28 | 2018-07-05 | Transgene Sa | Virus oncolytiques et molécules thérapeutiques |
US11565979B2 (en) | 2017-01-12 | 2023-01-31 | Pivot Bio, Inc. | Methods and compositions for improving plant traits |
US11739346B2 (en) | 2017-04-05 | 2023-08-29 | University Of Massachusetts | Minigene therapy |
WO2018204694A1 (fr) | 2017-05-03 | 2018-11-08 | Biomarin Pharmaceutical Inc. | Lentivirus améliorés pour la transduction de cellules souches hématopoïétiques |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2018232017A1 (fr) | 2017-06-13 | 2018-12-20 | Flagship Pioneering, Inc. | Compositions comprenant des curons et leurs utilisations |
US11759506B2 (en) | 2017-06-15 | 2023-09-19 | Voyager Therapeutics, Inc. | AADC polynucleotides for the treatment of Parkinson's disease |
US11773407B2 (en) | 2017-06-26 | 2023-10-03 | Arizona Board Of Regents On Behalf Of Arizona State University | CRISPR logic circuits for safer and controllable gene therapies |
US11890329B2 (en) | 2017-07-06 | 2024-02-06 | The Trustees Of The University Of Pennsylvania | AAV9-mediated gene therapy for treating mucopolysaccharidosis type I |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
WO2019020543A1 (fr) | 2017-07-28 | 2019-01-31 | Transgene Sa | Virus oncolytiques exprimant des agents ciblant des modulateurs immunitaires métaboliques |
WO2019028306A2 (fr) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions et procédés permettant l'administration de virus adéno-associés |
EP3808849A1 (fr) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration d'aav |
US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
WO2019060726A1 (fr) | 2017-09-22 | 2019-03-28 | Genzyme Corporation | Variant d'arni |
US11603529B2 (en) | 2017-09-22 | 2023-03-14 | Genzyme Corporation | Variant RNAi |
US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
EP4124658A2 (fr) | 2017-10-16 | 2023-02-01 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
WO2019079240A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
US11931375B2 (en) | 2017-10-16 | 2024-03-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
US11697801B2 (en) | 2017-12-19 | 2023-07-11 | Akouos, Inc. | AAV-mediated delivery of therapeutic antibodies to the inner ear |
WO2019173434A1 (fr) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Génomes aav partiels auto-complémentaires fabriqués par des cellules d'insectes |
EP4169576A1 (fr) | 2018-03-23 | 2023-04-26 | University of Massachusetts | Therapeutique genique pour le traitement de troubles osseux |
WO2019191701A1 (fr) | 2018-03-30 | 2019-10-03 | The Board Of Trustees Of Leland Stanford Junior University | Nouvelles capsides du virus adéno-associé recombinant présentant un tropisme pancréatique humain amélioré |
US11608510B2 (en) | 2018-03-30 | 2023-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
WO2019210269A1 (fr) | 2018-04-27 | 2019-10-31 | University Of Massachusetts | Capsides de vaa identifiés par la sélection d'une bibliothèque in vivo |
WO2019210137A1 (fr) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Procédés de mesure de la puissance de vecteurs viraux aadc |
WO2019217582A1 (fr) | 2018-05-08 | 2019-11-14 | Rutgers, The State University Of New Jersey | Protéines de polymérisation de lieur-laminine compatibles avec aav |
US11739345B2 (en) | 2018-05-09 | 2023-08-29 | Biomarin Pharmaceutical Inc. | Methods of treating phenylketonuria |
US11821008B2 (en) | 2018-05-14 | 2023-11-21 | Biomarin Pharmaceutical Inc. | Liver targeting adeno-associated viral vectors |
WO2019222136A2 (fr) | 2018-05-14 | 2019-11-21 | Biomarin Pharmaceutical Inc. | Nouveaux vecteurs viraux adéno-associés ciblant le foie |
WO2019222329A1 (fr) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration de vaa |
WO2019222328A1 (fr) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions et méthodes pour le traitement de la maladie de parkinson |
WO2019222441A1 (fr) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Sérotypes de vaa pour l'administration de charge utile spécifique au cerveau |
WO2019222444A2 (fr) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Évolution dirigée |
WO2019239311A1 (fr) | 2018-06-12 | 2019-12-19 | Glaxosmithkline Biologicals Sa | Polynucléotides et polypeptides d'adénovirus |
WO2020010042A1 (fr) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique et de troubles associés à la moelle épinière |
WO2020023612A1 (fr) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systèmes et méthodes de production de formulations de thérapie génique |
WO2020028816A1 (fr) | 2018-08-03 | 2020-02-06 | Genzyme Corporation | Variante d'arni contre l'alpha-synucléine |
WO2020072683A1 (fr) | 2018-10-02 | 2020-04-09 | Voyager Therapeutics, Inc. | Redirection de tropisme de capsides aav |
WO2020072849A1 (fr) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Procédés de mesure du titre et de la puissance de particules de vecteur viral |
WO2020077165A1 (fr) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions et procédés pour l'administration d'aav |
EP4306961A2 (fr) | 2018-10-25 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Procédés d'analyse d'une composition de protéine de capside virale |
WO2020086893A1 (fr) | 2018-10-25 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Procédés d'analyse d'une composition de protéines de capside virale |
US11884925B2 (en) | 2018-11-08 | 2024-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Synthetic immunomodulation with a CRISPR super-repressor in vivo |
WO2020112967A1 (fr) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation de sptlc1 par l'intermédiaire de vecteurs adéno-associés recombinés |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
US11446344B1 (en) | 2018-12-12 | 2022-09-20 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
WO2020136232A1 (fr) | 2018-12-28 | 2020-07-02 | Transgene Sa | Protéine m2 à propriété immunosuppressive |
WO2020150556A1 (fr) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Procédés et systèmes de fabrication de particules aav |
WO2020172537A1 (fr) | 2019-02-22 | 2020-08-27 | University Of Massachusetts | Thérapie génique avec oxr1 |
WO2020190363A1 (fr) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Contrôle de la fixation de l'azote dans les bactéries rhizobium s'associant à des céréales |
WO2020191201A1 (fr) | 2019-03-19 | 2020-09-24 | Massachusetts Institute Of Technology | Contrôle de la fixation d'azote par rhizobium s'associant à des céréales |
WO2020223274A1 (fr) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | Système et procédé pour la production de cellules d'insectes infectées par baculovirus (ceib) dans les bioréacteurs |
WO2020227515A1 (fr) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines |
WO2020232044A1 (fr) | 2019-05-14 | 2020-11-19 | Biomarin Pharmaceutical Inc. | Méthodes de redosage de vecteurs de thérapie génique |
WO2021021674A1 (fr) | 2019-07-26 | 2021-02-04 | Akouos, Inc. | Méthodes de traitement de la perte auditive à l'aide d'une protéine cible sécrétée |
WO2021030125A1 (fr) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs |
WO2021041485A1 (fr) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Expression contrôlée de protéines virales |
WO2021046155A1 (fr) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Édition vectorisée d'acides nucléiques pour corriger des mutations manifestes |
WO2021050970A1 (fr) | 2019-09-13 | 2021-03-18 | Rutgers, The State University Of New Jersey | Protéines de polymérisation de lieur-laminine compatibles avec aav |
WO2021062164A1 (fr) | 2019-09-27 | 2021-04-01 | Biomarin Pharmaceutical Inc. | Caractérisation de particules virales de thérapie génique à l'aide de technologies de chromatographie d'exclusion stérique et de diffusion de lumière multi-angle |
WO2021155137A1 (fr) | 2020-01-29 | 2021-08-05 | Genzyme Corporation | Protéines de capside de virus adéno-associés modifiés pour thérapie génique oculaire et leurs procédés d'utilisation |
WO2021168362A1 (fr) | 2020-02-21 | 2021-08-26 | Akouos, Inc. | Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain |
US11807867B2 (en) | 2020-02-21 | 2023-11-07 | Akouos, Inc. | Compositions and methods for treating non-age-associated hearing impairment in a human subject |
WO2021202494A1 (fr) | 2020-03-31 | 2021-10-07 | University Of Massachusetts | Variants capsidiques de vaa et leurs utilisations |
WO2021202651A1 (fr) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection de tropisme de capsides de vaa |
WO2021207592A1 (fr) | 2020-04-09 | 2021-10-14 | 4Mvac Llc | Utilisation de vecteurs viraux pour la production de vaccins contre le coronavirus |
WO2021211753A1 (fr) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Composés de liaison à la protéine tau |
WO2021214443A1 (fr) | 2020-04-20 | 2021-10-28 | Synpromics Limited | Séquences d'acides nucléiques régulatrices |
WO2021231567A2 (fr) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions et méthodes pour traiter une perte auditive associée à slc26a4 |
WO2021231538A2 (fr) | 2020-05-13 | 2021-11-18 | Akouos, Inc. | Compositions et méthodes de traitement de perte auditive associée à kcnq4 |
WO2021230987A1 (fr) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection de tropisme de capsides de vaa |
WO2021247995A2 (fr) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la douleur neuropathique |
KR20230038496A (ko) | 2020-07-13 | 2023-03-20 | 트랜스진 | 면역 억제의 치료 |
WO2022013221A1 (fr) | 2020-07-13 | 2022-01-20 | Transgene | Traitement de la dépression immunitaire |
WO2022032153A1 (fr) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Milieu de culture cellulaire destiné à être utilisé dans la production de produits de thérapie génique dans des bioréacteurs |
WO2022032140A2 (fr) | 2020-08-07 | 2022-02-10 | Amicus Therapeutics, Inc. | Protéines de ciblage des vésicules et leurs utilisations |
WO2022051555A2 (fr) | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Constructions de phosphatase alcaline solubles et vecteurs d'expression comprenant un polynucléotide codant pour des constructions de phosphatase alcaline solubles |
WO2022049385A1 (fr) | 2020-09-04 | 2022-03-10 | Asklepios Biopharmaceutical, Inc. | Séquences d'acides nucléiques régulatrices |
WO2022094461A1 (fr) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Méthode d'enrichissement d'un virus adéno-associé |
WO2022119839A1 (fr) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Constructions d'anticorps anti-vegf et procédés associés pour le traitement de symptômes associés au neurinome de l'acoustique |
WO2022140560A1 (fr) | 2020-12-23 | 2022-06-30 | Flagship Pioneering Innovations V, Inc. | Assemblage in vitro de capsides d'anellovirus renfermant de l'arn |
WO2022146839A1 (fr) | 2020-12-29 | 2022-07-07 | Akouos, Inc. | Compositions et méthodes pour traiter une perte auditive et/ou une perte de la vision associées à clrn1 |
WO2022147480A1 (fr) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Virus oncolytique codant pour la sialidase et agent de ciblage de cellule immunitaire multispécifique |
WO2022147481A1 (fr) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Polythérapie d'un virus oncolytique délivrant un antigène étranger et cellule immunitaire modifiée exprimant un récepteur chimérique ciblant l'antigène étranger |
WO2022187473A2 (fr) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Expression contrôlée de protéines virales |
WO2022187548A1 (fr) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Expression régulée de protéines virales |
WO2022214632A1 (fr) | 2021-04-07 | 2022-10-13 | Neoplants Sas | Compositions et procédés d'assainissement d'air intérieur |
WO2022235586A1 (fr) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Procédés de génération de cellules endothéliales cornéennes matures |
WO2023019203A1 (fr) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Systèmes inductibles pour modifier l'expression génique dans des cellules hypoimmunogènes |
WO2023034989A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034980A1 (fr) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034996A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034994A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034990A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023034997A1 (fr) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Compositions capsidiques de vaa et méthodes d'administration |
WO2023044483A2 (fr) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement du cancer positif her2 |
WO2023056329A1 (fr) | 2021-09-30 | 2023-04-06 | Akouos, Inc. | Compositions et méthodes de traitement de perte auditive associée à kcnq4 |
WO2023081648A1 (fr) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Variants capsidiques de vaa et utilisations associées |
WO2023091948A1 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Variants de capsides d'aav et leurs utilisations |
WO2023107188A1 (fr) | 2021-12-10 | 2023-06-15 | Massachusetts Institute Of Technology | Prédiction, biosynthèse et intégration en tant que biodétecteurs de molécules portant des signes d'absorption de la lumière uniques, et de leur détection à distance sur le terrain au moyen de caméras multispectrales ou hyperspectrales |
WO2023111580A1 (fr) | 2021-12-16 | 2023-06-22 | University Of Dundee | Dégradation ciblée de l'alpha-synucléine |
WO2023147374A2 (fr) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Système d'expression de baculovirus |
WO2023150142A1 (fr) | 2022-02-02 | 2023-08-10 | Akouos, Inc. | Constructions d'anticorps anti-vegf et méthodes associées pour le traitement de symptômes associés au schwannome vestibulaire |
WO2023154693A1 (fr) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Variants de capside d'aav et leurs utilisations |
WO2023152504A1 (fr) | 2022-02-10 | 2023-08-17 | University Of Dundee | Système de phosphatase dirigé par affinité pour la déphosphorylation ciblée de protéines |
WO2023196862A1 (fr) | 2022-04-06 | 2023-10-12 | Genzyme Corporation | Thérapie génique ciblée pour la dystrophie myotonique dm-1 |
WO2023201273A1 (fr) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Dosage de cellules dendritiques pour l'immunogénicité innée d'agents de thérapie génique |
WO2023201272A1 (fr) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Utilisation de modulateurs irak4 pour la thérapie génique |
WO2023201274A1 (fr) | 2022-04-12 | 2023-10-19 | Genzyme Corporation | Utilisation d'un modulateur irak4 pour la thérapie génique |
WO2023200843A1 (fr) | 2022-04-12 | 2023-10-19 | The Broad Institute, Inc. | Compositions et méthodes de criblage d'éléments régulateurs cis |
WO2023213763A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus codant pour un agent de liaison comprenant un sdab anti-pd-l1 |
WO2023213764A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf |
WO2023220729A2 (fr) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Compositions d'adn à double brin et procédés associés |
WO2023235791A1 (fr) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Variants de capside de vaa et leurs utilisations |
WO2024006741A1 (fr) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Variants de capside d'aav et leurs utilisations |
WO2024003353A1 (fr) | 2022-07-01 | 2024-01-04 | Transgene | Protéine de fusion comprenant une protéine d tensioactive et un élément de la tnfsf |
WO2024011112A1 (fr) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Variants de capside d'aav et leurs utilisations |
WO2024009280A1 (fr) | 2022-07-08 | 2024-01-11 | Baylor College Of Medicine | Inhibiteurs de réponse au stress intégrés et leurs méthodes d'utilisation |
WO2024054983A1 (fr) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Expression controlée de protéines virales |
WO2024059739A1 (fr) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Composés de liaison à la protéine tau |
WO2024064856A1 (fr) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Traitement de la cardiomyopathie au moyen de vecteurs de thérapie génique aav |
WO2024064863A2 (fr) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Traitement de la cardiomyopathie arythmogène avec des vecteurs de thérapie génique aav |
EP4345106A1 (fr) | 2022-09-30 | 2024-04-03 | Charité - Universitätsmedizin Berlin | Vecteurs de thérapie génique pour l'expression de variants de préprodyrphine pour le traitement de l'épilepsie |
WO2024069010A1 (fr) | 2022-09-30 | 2024-04-04 | Charité - Universitätsmedizin Berlin | Vecteurs de thérapie génique pour l'expression de variants de préprodynorphine pour le traitement de l'épilepsie |
Also Published As
Publication number | Publication date |
---|---|
CA2264482A1 (fr) | 1998-03-12 |
EP0931158A1 (fr) | 1999-07-28 |
JP2001500015A (ja) | 2001-01-09 |
AU4183397A (en) | 1998-03-26 |
AU722624B2 (en) | 2000-08-10 |
IL128780A0 (en) | 2000-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU722624B2 (en) | An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase | |
US6274354B1 (en) | Methods using cre-lox for production of recombinant adeno-associated viruses | |
AU723497C (en) | Method for recombinant adeno-associated virus-directed gene therapy | |
WO1998010086A9 (fr) | Procede d'utilisation de cre-lox pour la production de virus adeno-associes de recombinaison | |
US20020037867A1 (en) | Method for recombinant adeno-associated virus-directed gene therapy | |
US6251677B1 (en) | Hybrid adenovirus-AAV virus and methods of use thereof | |
AU695811B2 (en) | Hybrid adenovirus-AAV virus and methods of use thereof | |
US8241622B2 (en) | Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences | |
US20040224411A1 (en) | Recombinant adeno-associated virus production | |
CN1234735A (zh) | 治疗皮肤色素沉着的方法 | |
US20100278791A1 (en) | Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same | |
CN103764831A (zh) | 不含衣壳的aav载体、组合物以及制备载体和基因递送的方法 | |
CN109321587B (zh) | 一种acat1基因干扰的嵌合抗原受体t细胞 | |
CN101463362B (zh) | 融合表达绿色荧光蛋白的表达载体及其构建方法与应用 | |
AU2021270526B2 (en) | Gene therapy with dysferlin dual vectors | |
MXPA99002215A (en) | Method for recombinant adeno-associated virus-directed gene therapy | |
CN114032217A (zh) | 基于dna载体和复制型痘苗病毒载体的新冠病毒复合型疫苗 | |
WO2003084977A1 (fr) | Systeme de regulation de l'expression genique et son utilisation dans les lignees cellulaires d'incorporation de virus recombinants | |
KR20230085912A (ko) | Cd14 프로모터를 갖는 재조합 아데노 관련 바이러스 벡터 및 이의 용도 | |
CN116769811A (zh) | 分泌trail的工程化巨噬细胞及其应用 | |
CN114921394A (zh) | 一种重组绵羊李斯特菌及其使用方法 | |
MXPA97003105A (en) | Hybrid adenovirus-virus aav and mi method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09242742 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 512963 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2264482 Country of ref document: CA Kind code of ref document: A Ref document number: 2264482 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/002216 Country of ref document: MX Ref document number: 1997939829 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997939829 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997939829 Country of ref document: EP |